Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Acute Ischemic Stroke Drugs Market from 2024 to 2025?

The market size of drugs for acute ischemic stroke has seen robust growth in the past years. The market, which was worth $13.5 billion in 2024, is projected to increase to $14.21 billion in 2025, representing a compound annual growth rate (CAGR) of 5.3%. The growth observed in the historic period is due to factors such as the rising occurrence of stroke, government schemes and health policies, enhanced awareness and education, strategic alliances and collaborations, and an aging population.

What Is the Projected Market Size of the Acute Ischemic Stroke Drugs Market?

Expectations are growing for robust expansion in the acute ischemic stroke drugs market over the ensuing years, with projections of it swelling to “$17.96 billion by 2029 at a compound annual growth rate (CAGR) of 6.0%. Factors contributing to the anticipated growth within this timeframe include the development of new therapies and a robust drug pipeline, advancements in personalized medicine, improvements in global healthcare infrastructure, escalating healthcare expenditure, coupled with telemedicine and remote patient monitoring trends. Key developments expected in this period include the progression of thrombolytic therapies, the evolution of neuroprotective agents, research in personalized medicine and biomarkers, and the advent of remote healthcare services, all supported by a host of collaborations and strategic partnerships.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10049&type=smp

Who are the Major Competitors in the Acute Ischemic Stroke Drugs Market Outlook?

Major companies operating in the acute ischemic stroke drugs market include F. Hoffmann-La Roche AG, C.H. Boehringer Sohn AG & Co. KG, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, AstraZeneca plc, ZZ Biotech LLC, NoNO Inc., Biogen Inc., Athersys Inc., Bayer AG, Sanofi S.A., Pfizer Inc., DiaMedica Therapeutics, Lumosa Therapeutics Co. Ltd., Johnson & Johnson, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals LLC, Nanjing Yoko Biomedical Co. Ltd., TrueBinding Inc., GNT Pharma Co. Ltd., aptaTargets SL, NuvOX Pharma, Simcere Pharmaceutical Co. Ltd., Genentech Inc., Pharming Technologies B.V., SanBio BV, Revalesio Corporation, Stemedica Cell Technologies Inc., CorInnova Incorporated, Phagenesis

What Is Fueling Growth in the Acute Ischemic Stroke Drugs Market?

The growing occurrence of long-term illnesses is expected to spur the expansion of the acute ischemic stroke medication market in the foreseeable future. Chronic diseases, otherwise termed as non-transmissible diseases, pertain to conditions that persist for one year or more and need continuous medical care, impede everyday actions, or both. Chronic ailments like heart diseases, cancer, and diabetes are the major causes of death and disability. Acute ischemic stroke medicines are predominantly used in chronic ailments to diminish clot formation and stroke probabilities and replenish cerebral blood flow. For example, in September 2022, the World Health Organization (WHO), a health agency based in Switzerland, reported that chronic diseases contribute to about 41 million deaths every year, representing 74% of global deaths, with 17 million people dying from chronic diseases before reaching 70 years old. It is projected that by 2025, approximately 164 million Americans, nearly 49% of the population, would be suffering from chronic illnesses. Thus, the surge in chronic disease prevalence is fueling the acute ischemic stroke medication market’s development.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10049&type=smp

Which Acute Ischemic Stroke Drugs Market Segments Are Growing the Fastest?

The acute ischemic stroke drugs market covered in this report is segmented –

1) By Type: Tablet, Capsule, Other Types

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Hospitals, Diagnostic Centers, Other Applications

Subsegments:

1) By Tablet: Immediate Release Tablets, Extended Release Tablets, Orally Disintegrating Tablets

2) By Capsule: Hard Shell Capsules, Soft Gelatin Capsules, Extended Release Capsules

3) By Other Types: Injectable Solutions, Intravenous (IV) Preparations, Inhalation Formulations

Which Industry Trends Are Shaping the Future of the Acute Ischemic Stroke Drugs Market?

Key players in the acute ischemic stroke drug market are focusing on creating groundbreaking formulations such as under-the-tongue versions of edaravone and dexborneol for acute ischemic stroke. The sublingual treatment involving edaravone and dexborneol, when placed beneath the tongue, is quickly absorbed into the bloodstream, harnessing the antioxidant and anti-inflammatory benefits of both substances to increase treatment effectiveness. For example, in October 2024, Simcere Pharmaceutical, a pharmaceutical firm based in China, received a breakthrough therapy designation for Sanbexin, a sublingual version of edaravone and dexborneol, aimed at acute ischemic stroke (AIS) treatment. This designation was fueled by encouraging outcomes from the TASTE-SL phase 3 clinical trial (NCT04950920), where Sanbexin treatment led to a modified Rankin Scale (mRS) score of ≤1 at 90 days in 64.4% of patients, as opposed to 54.7% in the group receiving a placebo. The remedy, which is deliverable outside of hospital environments, seeks to minimize disability and enhance results for individuals with AIS.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-drugs-global-market-report

Which Countries Are Leading the Acute Ischemic Stroke Drugs Market?

North America was the largest region in the acute ischemic stroke drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global acute ischemic stroke drugs market report during the forecast period. The regions covered in the acute ischemic stroke drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10049

This Report Delivers Insight On:

1. How big is the acute ischemic stroke drugs market, and how is it changing globally?

2. Who are the major companies in the acute ischemic stroke drugs market, and how are they performing?

3. What are the key opportunities and risks in the acute ischemic stroke drugs market right now?

4. Which products or customer segments are growing the most in the acute ischemic stroke drugs market?

5. What factors are helping or slowing down the growth of the acute ischemic stroke drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model